Details of Disease

General Information of Disease (ID: DISAIU45)

Disease Name	Hepatic veno-occlusive disease
Synonyms	veno-occlusive disease; liver veno-occlusive disease; hepatic Vod; sinusoidal obstruction syndrome; Budd Chiari Syndrome
Disease Class	DB98: Liver vascular disorder
Definition	Hepatic veno-occlusive disease (hepatic VOD) is a condition resulting from toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins.
Disease Hierarchy	DISW8GMJ: Hepatic vascular disorder DISAIU45: Hepatic veno-occlusive disease
ICD Code	ICD-11 ICD-11: DB98.6 ICD-10 ICD-10: K76.5 Expand ICD-11 'DB98.6 Expand ICD-10 'K76.5
Disease Identifiers	MONDO ID MONDO_0019514 MESH ID D006504 UMLS CUI C0019156 MedGen ID 5514 Orphanet ID 890 SNOMED CT ID 65617004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Defibrotide	DM6CWSO	Approved	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD22	TTM6QSK	Limited	Biomarker	[2]
THBD	TTAPV67	Disputed	Biomarker	[3]
GSTA1	TT4P8DE	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FBL	OTRODIE5	Strong	Biomarker	[5]
OCLN	OTSUTVWL	Strong	Biomarker	[6]
SP110	OTFW6WH7	Strong	Genetic Variation	[7]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208114
2	No free rides: management of toxicities of novel immunotherapies in ALL, including financial.Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):25-34. doi: 10.1182/asheducation-2018.1.25.
3	Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.In Vivo. 2018 Nov-Dec;32(6):1409-1417. doi: 10.21873/invivo.11393.
4	Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
5	Estimation of the future remnant liver function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores.Eur J Surg Oncol. 2017 Dec;43(12):2277-2284. doi: 10.1016/j.ejso.2017.08.009. Epub 2017 Sep 4.
6	The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2006 Oct;80(4):375-83. doi: 10.1016/j.clpt.2006.07.002.
7	Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome.J Allergy Clin Immunol. 2012 Sep;130(3):735-742.e6. doi: 10.1016/j.jaci.2012.02.054. Epub 2012 May 21.